Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Basal/HER2 breast carcinomas

15 Jan 2013

Abstract excerpt

High rates of inherent primary resistance to the humanized monoclonal antibody trastuzumab (Herceptin) are frequent among HER2 gene-amplified breast carcinomas in both metastatic and adjuvant settings. The clinical efficacy of trastuzumab is highly correlated with its ability to specifically and efficiently target HER2-driven populations of breast cancer stem cells (CSCs). Intriguingly, many of the possible...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer and Skin Lesions
Share to Hedgehog Signaling Pathway Studies
Share to Nonmelanoma Skin Cancer Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23255137
DOI: 10.4161/cc.23274

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Basal/HER2 breast carcinomasPMID 23255137Read ↗

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.Semantic proximity Read ↗

Cancer stem cells and HER2 positive breast cancer: The story so farSemantic proximity Read ↗

Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin)Semantic proximity Read ↗

miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancerSemantic proximity Read ↗

Therapeutic vulnerabilities in triple negative breast cancer: Stem-like traits explored within molecular classification.Semantic proximity Read ↗

Epithelial‐to‐mesenchymal transition and cancer stem cells contribute to breast cancer heterogeneitySemantic proximity Read ↗

Human Primary Breast Cancer Stem Cells Are Characterized by Epithelial-Mesenchymal PlasticitySemantic proximity Read ↗

Cancer stem cells are prevalent in the basal-like 2 and mesenchymal triple-negative breast cancer subtypes in vitroSemantic proximity Read ↗

Immunotherapy Implication of Signature-Guided Biomarker Discovery for Trastuzumab-Resistant HER2-Positive Breast CancerSemantic proximity Read ↗

Breast cancer stem cells mediated CD8 <sup>+</sup> T cell exhaustion among different molecular subtypes of breast cancer regulated via NOTCH1/RBPJ/PD-L1 axisSemantic proximity Read ↗

miR‐200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancerSemantic proximity Read ↗

HER-2, Notch, and Breast Cancer Stem Cells: Targeting an Axis of EvilSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.